Nanomedicine News

RSS

Sienna Labs Secures Key Patent on Targeted Plasmonic Therapy Platform to Treat Sebaceous Glands and Hair

Sienna Labs announced today that the U.S. Patent and Trademark Office issued U.S. Patent No. 8,906,418 covering, among other aspects, methods of using the company's targeted plasmonic therapy (TPT) platform for localizing thermal damage to sebaceous glands and hair, a key mechanism for their investigational acne treatment and hair removal indications.

22 Dec 2014

Celator Pharmaceuticals Announces Receipt of European Patent Allowance on Nanoparticle Delivery Technology

Celator Pharmaceuticals, Inc., a biopharmaceutical company transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that the application of European patent number 2,222,278 was allowed by the European Patent Office.

22 Dec 2014

First Patient Dosed in Cerulean CRLX301 Nanoparticle-Drug Conjugate Trial for Advanced Solid Tumors

Cerulean Pharma Inc., a leader in Dynamic Tumor Targeting™, today announced that the first patient has been dosed with CRLX301 in Cerulean’s Phase 1/2a trial in patients with advanced solid tumor malignancies. CRLX301 is a nanoparticle-drug conjugate, or NDC, with a docetaxel payload, and it is the second clinical candidate from Cerulean’s Dynamic Tumor Targeting Platform.

19 Dec 2014

Distinguished Contributor to Green Nanotechnology and Nanomedicine Elected into Fellowship of National Academy of Inventors

Nanomedicine is the medical application of nanotechnology, or the use of microscopic structures to diagnose, image, treat and prevent disease. Current problems in nanomedicine include understanding and anticipating the potentially toxic impact these nanostructures have on the body and the environment once they're released.

18 Dec 2014

Nanoparticle System Decorated with Nanobodies to Locate Cellular Source of Brain Damage

Traumatic brain injury is currently revealed by using a series of physiological and cognitive tests along with standard medical imaging, such as magnetic resonance imaging (MRI). The techniques are excellent for diagnosis of moderate to severe traumatic brain injury, but less effective for diagnosing mild injury and for predicting the extent of its impact.

From Arizona State University 17 Dec 2014

NetScientific Invests in PDS Biotechnology

NetScientific, the biomedical and healthcare technology group, today announced it has made an investment in PDS Biotechnology Corporation (‘PDS’).

16 Dec 2014

Cristal Therapeutics Completes New €6 Million Financing Round

Biopharmaceutical company Cristal Therapeutics has completed a new financing round of over €6 million which includes investments from new and existing investors and a national innovation fund. Venture capital investor Chemelot Ventures joins as a new shareholder and existing investors Thuja Capital, BioGeneration Ventures, Nedermaas, Utrecht University Holding and Beheer Innovatiefonds Provincie Limburg also contributed.

16 Dec 2014

Gold Nanoparticle Sensor System Can Accurately Profile Anti-Cancer Drugs

Traditional genomic, proteomic and other screening methods currently used to characterize drug mechanisms are time-consuming and require special equipment, but now researchers led by chemist Vincent Rotello at the University of Massachusetts Amherst offer a multi-channel sensor method using gold nanoparticles that can accurately profile various anti-cancer drugs and their mechanisms in minutes.

16 Dec 2014

NantWorks and Sorrento to Establish The Immunotherapy Antibody JV

Sorrento Therapeutics, Inc., an oncology company developing new treatments for cancer and associated pain, announced today that it has entered into a binding agreement with NantWorks founder, physician scientist, and biotechnology entrepreneur Dr. Patrick Soon-Shiong.

16 Dec 2014

Nanomaterial Coatings Improve Strength, Biocompatibility of Hip and Knee Replacements

Washington State University researchers are working to improve materials used in hip and knee replacements so that they last longer and allow patients to quickly get back on their feet after surgery.

15 Dec 2014

Nanomedicine News

Sienna Labs Secures Key Patent on Targeted Plasmonic Therapy Platform to Treat Sebaceous Glands and Hair

Celator Pharmaceuticals Announces Receipt of European Patent Allowance on Nanoparticle Delivery Technology

First Patient Dosed in Cerulean CRLX301 Nanoparticle-Drug Conjugate Trial for Advanced Solid Tumors

Distinguished Contributor to Green Nanotechnology and Nanomedicine Elected into Fellowship of National Academy of Inventors

Nanoparticle System Decorated with Nanobodies to Locate Cellular Source of Brain Damage

NetScientific Invests in PDS Biotechnology

Cristal Therapeutics Completes New €6 Million Financing Round

Gold Nanoparticle Sensor System Can Accurately Profile Anti-Cancer Drugs

NantWorks and Sorrento to Establish The Immunotherapy Antibody JV

Nanomaterial Coatings Improve Strength, Biocompatibility of Hip and Knee Replacements

Combining Nanofluids and Turbulators for Sustainable Energy

Enhancing Material Properties through Nanotube Encapsulation

Brain-Inspired Nano-Tech Promises New Era for Electronics

Breakthrough in 2D Material Growth Opens Doors to Cleaner Energy and Next-Generation Technology

Sustainable Carbon Nanomaterial Gii Set to Transform Energy Storage in Internet of Things Devices

Electrospinning and the Future of Nanotechnology

How Electrospinning is Shaping the Future of Nanotechnology

Conversations on AFM: Applications of BioAFM in Life Science

Sponsored Content

Characterization of Active Pharmaceutical Ingredients, Injectables, and Proteins

The Future of Wound Care: Why Nanofibers are Key to Accelerated Healing

The Evolution of Lipid Nanoparticles

How Emulsion Electrospinning is Transforming Materials